No Data
Is Gilead Sciences Gaining or Losing Market Support?
FDA Commissioner Nominee Makary Advances to Full Senate Vote
Reported Earlier, Zai Lab's BLA For TIVDAK Accepted In China For Recurrent Or Metastatic Cervical Cancer
BEIGENE: AI has been widely applied to the clinical development stage and is working to expand the new "NewCo" model.
① BEIGENE believes that companies with a diversified Global layout can better distribute R&D costs across different regions compared to those focused on a single market. Attracting capital through the NewCo model can maximize the value of various potential pipelines; ② Company Executives believe that in the early stages of drug development, AI has not yet played a critical role, and caution is needed regarding the "bubble" created by market hype.
Gilead Presents New HIV Treatment And Cure Research Data
Merck Releases Positive Phase 3 Data on Daily Oral HIV Drug
lightfoot : junk, hook, line and sinker
Wonder-Man : great post. thank you for sharing
Christopher Flint197 : like to learn what a swing trade looks like and when to get in and out.